中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2015年
6期
807-810
,共4页
付娟%张爱云%杨欣%罗爱华%姚霞%尹宜发
付娟%張愛雲%楊訢%囉愛華%姚霞%尹宜髮
부연%장애운%양흔%라애화%요하%윤의발
有机铂化合物/投药和剂量%顺铂/投药和剂量%放射疗法%药物疗法%宫颈肿瘤/治疗
有機鉑化閤物/投藥和劑量%順鉑/投藥和劑量%放射療法%藥物療法%宮頸腫瘤/治療
유궤박화합물/투약화제량%순박/투약화제량%방사요법%약물요법%궁경종류/치료
Organoplatinum compounds/AD%Cisplatin/AD%Radiotherapy%Drug therapy%Uterine cervical neoplasms/TH
目的 通过比较奈达铂或顺铂同步放化疗治疗对局部晚期宫颈癌患者的作用,探析上述两种药物的临床疗效.方法 分析2009年2月至2011年11月在本院接受治疗的54例局部晚期宫颈癌患者的临床资料.按随机数字表法将入选者分为DDP组(顺铂组)和NDP组(奈达铂组)两组,每组27例.比较两组患者的基线资料、近期疗效、远期疗效以及不良反应.结果 两组患者的一般资料包括性别、年龄、BMI、分期、病理比较差异均无统计学意义(P>0.05).两组的有效率(RR)均为100%,其中NDP组的完全缓解(CR)率(74.1%)与DDP组(63.0%)比较差异无统计学意义(P>0.05).两组≤60岁的患者中,CR率、1、2、3年的生存率、中位无进展生存期(PFS)比较差异均无统计学意义(P>0.05);>60岁患者中,1、2、3年的生存率、中位PFS比较差异均无统计学意义(P>0.05),但是两组的CR率比较差异有统计学意义(P<0.05).在非血液学毒性上,NDP组发生恶心呕吐的几率、对于肾功能的影响明显比DDP组低(P<0.05);两组在肝功能受损上差异无统计学意义(P>0.05).在血液学毒性上,两组患者在贫血和白细胞下降发生率方面差异无统计学意义(P>0.05);NDP组发生血小板下降的几率明显比DDP组高(P<0.01),但是其主要体现在Ⅰ、Ⅱ级.结论 对于局部晚期宫颈癌的治疗,单药奈达铂与单药顺铂的同步放化疗的疗效相近,且顺铂的耐受性不及奈达铂.
目的 通過比較奈達鉑或順鉑同步放化療治療對跼部晚期宮頸癌患者的作用,探析上述兩種藥物的臨床療效.方法 分析2009年2月至2011年11月在本院接受治療的54例跼部晚期宮頸癌患者的臨床資料.按隨機數字錶法將入選者分為DDP組(順鉑組)和NDP組(奈達鉑組)兩組,每組27例.比較兩組患者的基線資料、近期療效、遠期療效以及不良反應.結果 兩組患者的一般資料包括性彆、年齡、BMI、分期、病理比較差異均無統計學意義(P>0.05).兩組的有效率(RR)均為100%,其中NDP組的完全緩解(CR)率(74.1%)與DDP組(63.0%)比較差異無統計學意義(P>0.05).兩組≤60歲的患者中,CR率、1、2、3年的生存率、中位無進展生存期(PFS)比較差異均無統計學意義(P>0.05);>60歲患者中,1、2、3年的生存率、中位PFS比較差異均無統計學意義(P>0.05),但是兩組的CR率比較差異有統計學意義(P<0.05).在非血液學毒性上,NDP組髮生噁心嘔吐的幾率、對于腎功能的影響明顯比DDP組低(P<0.05);兩組在肝功能受損上差異無統計學意義(P>0.05).在血液學毒性上,兩組患者在貧血和白細胞下降髮生率方麵差異無統計學意義(P>0.05);NDP組髮生血小闆下降的幾率明顯比DDP組高(P<0.01),但是其主要體現在Ⅰ、Ⅱ級.結論 對于跼部晚期宮頸癌的治療,單藥奈達鉑與單藥順鉑的同步放化療的療效相近,且順鉑的耐受性不及奈達鉑.
목적 통과비교내체박혹순박동보방화료치료대국부만기궁경암환자적작용,탐석상술량충약물적림상료효.방법 분석2009년2월지2011년11월재본원접수치료적54례국부만기궁경암환자적림상자료.안수궤수자표법장입선자분위DDP조(순박조)화NDP조(내체박조)량조,매조27례.비교량조환자적기선자료、근기료효、원기료효이급불량반응.결과 량조환자적일반자료포괄성별、년령、BMI、분기、병리비교차이균무통계학의의(P>0.05).량조적유효솔(RR)균위100%,기중NDP조적완전완해(CR)솔(74.1%)여DDP조(63.0%)비교차이무통계학의의(P>0.05).량조≤60세적환자중,CR솔、1、2、3년적생존솔、중위무진전생존기(PFS)비교차이균무통계학의의(P>0.05);>60세환자중,1、2、3년적생존솔、중위PFS비교차이균무통계학의의(P>0.05),단시량조적CR솔비교차이유통계학의의(P<0.05).재비혈액학독성상,NDP조발생악심구토적궤솔、대우신공능적영향명현비DDP조저(P<0.05);량조재간공능수손상차이무통계학의의(P>0.05).재혈액학독성상,량조환자재빈혈화백세포하강발생솔방면차이무통계학의의(P>0.05);NDP조발생혈소판하강적궤솔명현비DDP조고(P<0.01),단시기주요체현재Ⅰ、Ⅱ급.결론 대우국부만기궁경암적치료,단약내체박여단약순박적동보방화료적료효상근,차순박적내수성불급내체박.
Objective To investigate the clinical effect of cisplatin and nedaplatin through comparing the effects of synchronous radiotherapy and chemotherapy of cisplatin and nedaplatin on patients with locally advanced cervical cancers.Methods Clinical data of 54 cases of patients with locally advanced cervical cancers received treatment at our hospital from 2009 to 2011 were analyzed retrospectively.Patients were divided into two groups according to the treatment:group DDP (cisplatin) and group NDP (nedaplatin).The general information,short-term effect,long-term curative effect,and adverse reactions were compared between two groups.Results The general information including gender,age,body mass index (BMI),stages,and pathology had no statistically significant difference between two groups.The response rate (RR)of patients in each group was 100%.The complete remission (CR) rate between groups NDP and DDP had no statistically significant difference.Among the patients ≤60 years old,the CR rate,the survival rate of 1,2,and 3 years,and the median progression-free survival (PFS) had no statistically significant difference.Among the patients > 60 years old,the survival rate of 1,2,and 3 years,and the median PFS had no statistically significant difference,but the CR rate had statistically significant difference.In the non-hematological toxicity,the incidence rate of nausea and vomiting,the effect on renal function in group NDP were obviously lower than those in group DDP.There was no significant difference in liver function damage.In the hematological toxicity,there was no statistically significant difference in the incidence rate of anemia and leukopenia.The incidence rate of decrease of platelet in group NDP was higher than that in group DDP,but it was mainly reflected in the Ⅰ and the Ⅱ level.Conclusions Cisplatin had the same efficacy of concurrent chemoradiotherapy with nedaplatin for the treatment of locally advanced cervical carcinoma with a worse tolerance.